Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04621591 · ClinicalTrials.gov registry record · NA
Case Series With Saneso 360° Gastroscope
A NA study, sponsored by Saneso.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT04621591: Completed NA study, sponsored by Saneso.
NCT04621591 is a NA study that has completed, run by Saneso. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04621591, a NA study, has completed, sponsored by Saneso.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
To confirm the procedural performance of the Saneso 360° gastroscope in Esophago-gastro-duodenoscopy (EGD) procedures.
Primary Outcome
Procedure success is assessed at the end of the procedure 1). Procedure success is defined as by successful intubation of the third portion of the duodenum. Photograph of the third portion of the duodenum will be taken.
Interventions
- DEVICE Saneso 360° gastroscope
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2020-09-09 |
| Phase | NA |
What the finished NCT04621591 record still lists
NCT04621591 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Saneso 360° gastroscope is the first listed.
NCT04621591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04621591 about?
NCT04621591 is a clinical study titled "Case Series With Saneso 360° Gastroscope". To confirm the procedural performance of the Saneso 360° gastroscope in Esophago-gastro-duodenoscopy (EGD) procedures.
What is the current status of trial NCT04621591?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2020-08-01. Estimated completion is 2020-09-09.
What interventions are being tested in trial NCT04621591?
The interventions under investigation include: Saneso 360° gastroscope (DEVICE).
Who is sponsoring clinical trial NCT04621591?
This trial is sponsored by Saneso, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04621591's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI